Journal
CURRENT MEDICAL SCIENCE
Volume 39, Issue 6, Pages 874-882Publisher
SPRINGER
DOI: 10.1007/s11596-019-2118-z
Keywords
immune therapy; chimeric antigen receptor T cells; hematological malignancies
Categories
Funding
- Key Program of the National Natural Science Foundation (NNSF) of China [81230052, 81630006]
Ask authors/readers for more resources
As a rapidly progressing field in oncology, the adoptive transfer of T cells that have been genetically modified with chimeric antigen receptors (CARs) has shown striking efficacy in the management of hematological malignancies and has been reported in a number of clinical trials. Of note, CAR T cell therapy has shown extraordinary potential, especially in relapsed/refractory patients. However, there are still challenges regarding the further development of this strategy, spanning from engineering and manufacturing issues, to limited applications, to accompanying toxicities. In this review, we will summarize the general knowledge of this novel method, including receptor composition, applications, adverse events and challenges. Additionally, we will propose several comprehensive recommendations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available